High-dose chemotherapy, autologous bone marrow or stem cell transplantation and post-transplant consolidation chemotherapy in patients with advanced breast cancer

Bone Marrow Transplantation

Volumn 20, Issue 9, 1997, Pages 721-729

  Tallman, M S ^a   Rademaker, A W ^a   Jahnke, L ^a   Brown, S G ^a   Bauman, A ^a   Mangan, C ^a   Kelly, C ^a   Rubin, H ^a   Kies, M S ^a   Shaw, J ^a   Kiel, K ^a   Gordon, L I ^a   Gradishar, W J ^a   Winter, J N ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Breast cancer; Marrow; Transplantation

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; THIOTEPA;

ADULT; ADVANCED CANCER; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG MEGADOSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; NEUTROPHIL; PRIORITY JOURNAL; REMISSION; STEM CELL TRANSPLANTATION; THROMBOCYTE;

EID: 0030663702     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700962     Document Type: Article

References (41)

1. Clark G, Sledge GW, Osborne CK et al. Survival from first recurrence: relative importance of prognostic factors in 1015 breast cancer patients. J Clin Oncol 1978; 5: 55-61.
2. Tormey DC, Gelman, Band PR et al. Comparison of induction chemotherapies for metastatic breast cancer: an Eastern Cooperative Oncology Group trial. Cancer 1982; 50: 1235-1244.
3. Cummings FJ, Cehman R, Horton J. Comparison of CAF vs CMFP in metastatic breast cancer: analysis of prognostic factors. J Clin Oncol 1985; 3: 932-940.
4. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984; 2: 1281-1288.
5. Eder J, Antman J, Peters W et al. High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. J Clin Oncol 1986; 4: 1592-1597.
6. Williams S, Mick R, Desser R et al. High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer. J Clin Oncol 1989; 7: 1824-1830.
7. Eder J, Elias A, Shea T et al. A phase I-II study of cyclophosphamide, thiotepa and carboplatin with autologous bone marrow support for metastatic breast cancer. J Clin Oncol 1986; 4: 1592-1597.
8. Wallerstein R Jr, Spitzer G, Dunphy F et al. A phase II study of mitoxantrone, etoposide and thiotepa with autologous bone marrow support for patients with relapsed breast cancer. J Clin Oncol 1990; 8: 1782-1788.
9. Klumpp TR, Mangan KF, Glenn LD et al. Phase II pilot study of high-dose busulfan and CY followed by autologous BM in peripheral blood stem cell transplantation in patients with advanced chemosensitive breast cancer. Bone Marrow Transplant 1993; 11: 337-339.
10. Ayash LJ, Wheeler C, Fairclough D et al. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol 1995; 13: 2043-2049.
11. Peters WP, Shpall E, Jones RB et al. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 1988; 6: 1368-1376.
12. Antman JK, Ayash L, Elias A et al. A phase II study of high-dose cyclophosphamide, thiotepa and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 1992; 10: 102-110.
13. Kennedy M, Beveridge R, Rowley S et al. High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer. J Natl Cancer Inst 1991; 83: 920-926.
14. Mansi JL, Berger U, McDonnell T et al. The fate of bone marrow micrometastases in patients with primary breast cancer. J Clin Oncol 1989; 7: 445-449.
15. Ingle JM, Tormey DC, Tank T. The bone marrow examination in breast cancer: diagnostic considerations and clinical usefulness. Cancer 1978; 41: 670-674.
16. Diel IJ, Kaufman M, Goerner R et al. Detection of tumor cells in bone marrow of patients with primary breast cancer: a prognostic factor for distant metastases. J Clin Oncol 1992; 10: 1534-1539.
17. Redding WH, Monaghan P, Imrie SF et al. Detection of micrometastases in patients with primary breast cancer. Lancet 1983; 2: 1271-1274.
18. Kies MS, Gordon LI, Rosen ST et al. Autologous bone marrow transplantation in breast cancer: separation of clonogenic tumor cell colonies by gradient fractionation. Exp Hematol 1988; 16: 190-194.
19. Cote RJ, Rosen PP, Lesser ML et al. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol 1991; 9: 1749-1756.
20. Dearnaley DP, Ormerod MG, Sloan JP. Micrometastases in breast cancer. Long-term follow-up of the first patient cohort. Eur J Cancer 1991; 27: 235-239.
21. Oken MM, Davis TE, Creech RH et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
22. Wilcoxon F. Individual comparisons by ranking methods. Biometrics 1945; 1: 80-83.
23. Miller RG Jr. Simultaneous Statistical Inference: Normal Univariate Techniques. Springer-Verlag: New York, 1981, pp 67-70.
24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
25. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-170.
26. Peto R, Dike MC, Armitage P et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 1977; 35: 1-39.
27. Demagalhaes-Silverman M, Bloom E, Lembersky B et al. High-dose chemotherapy and autologous stem cell support followed by post-transplantation doxorubicin as initial therapy for metastatic breast cancer. Clin Cancer Res 1997; 3: 193-197.
28. Bast RC, Defavririis P, Lipton J et al. Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement. Cancer Res 1985; 45: 499-523.
29. Kennedy MJ, Davis D, Passos-Coelho J et al. Administration of human recombinant granulocyte colony-stimulating factor (Filgrastim) accelerates granulocyte recovery following high-dose chemotherapy and autologous marrow transplantation with 4-hydroperoxycyclophosphamide-purged marrow in women with metastatic breast cancer. Cancer Res 1993; 53: 5424-5428.
30. Shpall EJ, Jones RB, Bast RC et al. 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow inpatients receiving high-dose chemotherapy and autologous bone marrow support: a phase I trial. J Clin Oncol 1991; 9: 85-93.
31. Ross AA, Loudovaris M, Hazelton B et al. Immunocytochemical analysis of tumor cells in pre- and post-culture peripheral blood progenitor cell collections from breast cancer patients. Exp Hematol 1995; 23: 1478-1483.
32. Ross AA, Cooper BW, Lazarus M et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993; 82: 2605-2610.
33. Shpall EJ, Jones RB, Bearman SI et al. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. J Clin Oncol 1994; 12: 28-36.
34. Tyer CL, Vredenburgh JJ, Heimer M et al. Breast cancer cells are effectively purged from peripheral blood progenitor cells with an immunomagnetic technique. Clin Cancer Res 1996; 2: 81-86.
35. Peters WP, Jones RB, Vrendenburgh J et al. A large prospective, randomized trial of high-dose combination alkylating agents (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM). Proc Am Soc Clin Oncol 1996; 15: 149 (Abstr).
36. Peters WP, Ross M, Vredenburgh JJ et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993; 11: 1132-1143.
37. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995; 13: 2483-2489.
38. Protocol: Intergroup T90-0180 (PBT-1). A phase III randomized comparison of maintenance chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil versus high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin and autologous bone marrow support for women with metastatic breast cancer who are responding to conventional induction chemotherapy. 1990 (activated).
39. Clift RA, Buckner CD, Thomas ED et al. The treatment of acute nonlymphoblastic leukemia by allogeneic bone marrow transplantation. Bone Marrow Transplant 1987; 2: 243-258.
40. Protocol: Intergroup 0121. A phase III study of conventional adjuvant chemotherapy versus high-dose chemotherapy and autologous bone marrow transplantation or stem cell transplantation as adjuvant intensification therapy following conventional adjuvant chemotherapy in patients with stage II and III breast cancer at high risk of recurrence. 1991 (activated).
41. Protocol: Cancer and Leukemia Group B 9082. A randomized, comparative study of high-dose CDA/cDDP/BCNU and ABMS versus standard-dose CDA/cDDP/BCNU as consolidation to adjuvant CAF for patients with operable stage II or stage III breast cancer involving ≥10 axillary lymph nodes. 1991 (activated).